Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation
Autonomix Medical, Inc. is set to present exciting developments in AI applications for interventional radiology, focusing on the early results from its ongoing proof-of-concept (PoC) human clinical trial.
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) is a medical device company dedicated to advancing precision nerve-targeted treatments. The Company has announced that its technology and interim findings from clinical trials will be showcased in a podium presentation at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress in Lisbon.
“Engaging with the scientific community is a key focus for us as we implement our clinical strategy. We are excited to have our presentation accepted at this prestigious global congress and to be part of CIRSE’s newly introduced interactive area, SPHAIRE, which aims to enhance understanding of emerging technologies in Interventional Radiology. We believe that synchronizing the release of our data with our publication strategy is crucial for raising awareness about our innovative platform technology, and we eagerly anticipate participating in this significant event,” stated Brad Hauser, Chief Executive Officer of Autonomix.
Details of the Presentation
Here are the details of the upcoming presentation:
Title: Rethinking pain management: transforming patient outcomes with precision mapping technology and celiac nerve RF ablation in end-stage cancer
Session: Future AI Applications in Interventional Radiology
Presenter: Dr. Askar Sabirov, Primary Investigator for the Company’s ongoing PoC human clinical trial focused on pain associated with pancreatic cancer
Session Date and Time: Monday, September 16 from 11:15 AM – 12:15 PM ET
About Autonomix Medical, Inc.
Autonomix is a medical device company committed to pioneering innovative technologies that transform the diagnosis and treatment of diseases affecting the nervous system. The Company’s cutting-edge technology platform features a catheter-based microchip sensing array capable of detecting and differentiating neural signals with approximately 3,000 times greater sensitivity than current technologies. This advancement may enable, for the first time, transvascular diagnosis and treatment of peripheral nervous system diseases anywhere in the body.
Initially, the Company is focusing on developing this technology for pain management, with early trials targeting pancreatic cancer, a condition known for causing severe pain and lacking reliable treatment options. The technology serves as a platform to address a variety of indications, including cardiology, hypertension, and chronic pain management, across a broad spectrum of diseases. It is important to note that this technology is investigational and has not yet received marketing clearance in the United States.
For more information, visit autonomix.com and follow the Company on X, LinkedIn, Instagram, and Facebook.
Frequently Asked Questions
What is Autonomix Medical focusing on?
Autonomix Medical is dedicated to advancing precision nerve-targeted treatments for diseases that involve the nervous system.
What will be presented at the CIRSE Annual Congress?
The presentation will cover innovative pain management techniques utilizing precision mapping technology and RF ablation.
Who is the presenter for the session?
Dr. Askar Sabirov, the Primary Investigator for the ongoing PoC human clinical trial related to pain from pancreatic cancer, will be the presenter.
When will the presentation take place?
The presentation is scheduled for Monday, September 16, from 11:15 AM to 12:15 PM ET.
What is unique about Autonomix's technology?
This technology features a catheter-based microchip sensing array that detects neural signals with significantly higher sensitivity compared to existing technologies.
